Selective BET bromodomain inhibition as an antifungal therapeutic strategy
https://www.ncbi.nlm.nih.gov/pubmed/28516956
Candida albicans is a major human fungal pathogen. Resverlogix and Zenith have thousands of compounds in their small molecule libraries. Several of these may be able to discriminate CaBdf1 from human BET bromodomain proteins.
"These findings establish BET inhibition as a promising antifungal therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited without antagonizing human BET function."
"In summary, CaBdf1 and human BET BDs have distinct BETi-binding activity, supporting the feasibility of targeting CaBdf1 BDs with highly selective small-molecule inhibitors."
BDAZ